Ampersand Technologies is developing custom, precision genetic tests to enable evidence-based decision-making in horticulture, agriculture, biosecurity, and environmental monitoring.
The technology has emerged as a challenger to PCR in the molecular diagnostics space and is already being used for point-of-need human medical diagnostics. Ampersand’s objective is to bring this technology to sectors that stand to benefit from using molecular diagnostics at the point-of-need, and to build a connected solution, providing a clear pathway to implementation for end users.
Ampersand Technologies officially launched in August 2021. The start-up, which is being led by Dr. Richard Winkworth, received co-investment from Matū, a venture capital fund focused on early-stage science and technology, and Massey Ventures, the company responsible for commercialising innovative research at Massey University.
Company Details
- Employees
- 4
- Founded
- 2021
- Address
- Palmerston North, Nz
- Industry
- Biotechnology
- Website
- https://www.ampersandtech.co.nz/
- HQ
- Palmerston North
Ampersand Technologies Questions
Ampersand Technologies's website is https://www.ampersandtech.co.nz/
Ampersand Technologies's LinkedIn profile is https://nz.linkedin.com/company/ampersand-technologies
Ampersand Technologies has
4 employees.
View email and phone details for 4
employees at Ampersand Technologies.
Ampersand Technologies's industry is
Biotechnology
Ampersand Technologies's top competitors are
Ampersand Capital Partners,
Ampersand Ventures,
Glycosyn,
Momentum,
Kraig Biocraft Laboratories, Inc.,
Miruku,
Nutrition From Water™ (Nxw),
Svs Laboratories,
Daisy Lab,
Opo Bio.
Ampersand Technologies's categories are Biotechnology
Ampersand Technologies's founding year is 2021
